
    
      This study includes three periods. First a screening period of up to one week. Second an
      open-label treatment period of up to six weeks where all participants apply tacrolimus
      ointment. Third an open-label disease control period of up to six months where half of the
      participants apply tacrolimus ointment and the other half of the participants do not apply
      treatment.
    
  